CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. Risk increases when used with other central nervous system depressants. Avoid alcohol consumption with daridorexant.
- TRADE NAME: Quvivo (Idorsia)
- INDICATIONS: Insomnia
- CLASS: Orexin receptor antagonist
- HALF-LIFE: approximately 8 hours
- FDA APPROVAL DATE: 01/07/2022
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP3A4 inducers, CYP3A4 inhibitors, Diltiazem, Efavirenz, Itraconazole, Ranitidine, Ranitidine, Rifampin - PREGNANCY: No available data on daridorexant use in pregnant women to evaluate for drug-associated risks of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/18/2024
